Laurus Labs Limited received FDA approval on August 27, 2018, for its ANDA209882 to manufacture the oral tablet formulation of Metformin Hydrochloride, subject to specific conditions. This authorization enhances Laurus Labs' portfolio in the large-scale diabetes market, likely protecting the company from brand erosion and providing a stable revenue stream within the generic pharmaceutical landscape.